Oern joined the OrganOx board as Non-Executive Chairman in December 2020. Oern has a wealth of experience in the Health Tech sector and over the past 10 years he has focused his attention on developing and steering companies in this sector to realise their full potential.

Prior to this, Oern spent 12 years at Medtronic in different positions including SVP & President, where he led a successful transformation of their global cardiac surgery business. He also spent 6 years in senior management positions at Abbott Laboratories Inc.

Before joining the Life Science industry, Oern trained and worked as a physician in Oslo.

Peter is OrganOx Co-Founder and Chief Medical Officer, and has worked with Constantin and the OrganOx team for more than 20 years on the development of OrganOx's normothermic organ perfusion technology. Peter leads OrganOx's pre-clinical and clinical programmes of OrganOx's patented normothermic organ perfusion technology.

Peter is Professor of Transplantation at the University of Oxford and Director of the Oxford Transplant Centre, where he is responsible for the kidney, small bowel and pancreatic transplant programmes. Earlier in his career Peter was Clinical Director of the Transplant Centre at Addenbrooke’s Hospital, Cambridge, one of the UK’s leading liver transplant centres and visiting Assistant Professor of Surgery at Indiana University Medical Centre, USA, where he established their liver transplant programme.

Peter's research interests lie primarily in novel applications of normothermic organ perfusion, ranging from its use for extracorporeal support to preservation and repair prior to transplantation. He has published over 25 papers on the topic of normothermic perfusion, the basis of the OrganOx technology, as well as in the areas of clinical transplantation, immunosuppression, monoclonal antibodies, xenotransplantation, liver perfusion and aspects of general surgery.

Constantin is OrganOx Co-Founder and Chief Technical Officer and has worked with Peter and the OrganOx team for more than 20 years on the development of OrganOx's normothermic organ perfusion technology. Constantin leads OrganOx's technical development programmes.

Constantin is Professor of Biomedical Engineering at the University of Oxford and Director of the Oxford Institute of Biomedical Engineering. Constantin founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), he is also the Director of the Oxford Centre for Drug Delivery Devices (OxCD3).

Constantin's research interests include normothermic organ perfusion, drug delivery, acoustic cavitation and therapeutic ultrasound. Constantin received the 2017 Royal Academy of Engineering Silver Medal and was appointed as a Fellow of the Royal Academy of Engineering in 2019.

Craig joined OrganOx in December 2016, and took over the role of CEO from Dr Les Russell in January 2017.

Prior to joining OrganOx, Craig was Managing Director of the award-winning business Siemens Magnet Technology. During the period 2010—2016, he was also an executive member of the Siemens Healthcare MRI business, the undisputed market leader. During his time in these roles, Siemens Magnet Technology developed a revolutionary new magnet contained within the World's strongest clinical MRI system, the Siemens MRI 7 Tesla product, MAGNETOM Terra.

Craig is a fellow of the Institution of Mechanical Engineers, he holds a first degree from the University of Liverpool, and an MBA with Distinction from the acclaimed University of Warwick Business School.

Earlier in his career, he worked at Oxford Instruments, Amersham Plc and GE Healthcare in a variety of management and leadership roles, within the in vivo diagnostics sector.

Graham joined OrganOx as Chief Financial Officer in June 2019. He has significant experience of being part of a senior leadership team for growth SMEs, implementing financial controls & procedures for managing significant change and growth, building capability and infrastructure, driving profitability, cash generation and value inflection. Graham has been in life sciences since 2006 and has undertaken two IPOs, numerous fundraisings (raising approx. £100m at hVIVO) and negotiated a number of complex licensing transactions and joint ventures.

Graham started his career with PricewaterhouseCoopers for 13 years, qualifying as a Chartered Accountant and working across its audit, tax, consultancy, business process re-engineering and outsourcing divisions. In 2001 he joined buyingTeam Limited (subsequently renamed Proxima) as Finance & Operations Director and was influential in growing the business to become one of the UK’s leading purchasing services providers. From 2006 to 2010 he was at Neuropharm Group plc as Chief Financial Officer. From 2011 to 2018 he was at hVIVO plc (formerly Retroscreen Virology Group plc) as Chief Financial & Business Officer. Graham has a first-class BSc in Economics and Maths from the University of Bristol.

Matthew joined the OrganOx board as a Non-Executive Director in 2009, when the company spun-out from the University of Oxford. Matthew has over twenty years of experience as a venture investor, focusing on highly disruptive healthcare, medtech and life science opportunities. In addition to OrganOx, he sits on other boards including Caristo Diagnostics, OxSonics, Momentum BioSciences, BioFidelity and Lightcast Discovery.

Matthew has a D.Phil (Biochemistry) from Oxford. After a brief research career, he began investing in early stage companies through Oxford Technology Management, before co-founding Longwall Venture Partners. Longwall has raised three funds over the last decade, and invests in early stage, UK-based science, engineering and healthcare businesses

Tim joined the OrganOx board as a Non-Executive Director in January 2020 following the investment by BGF. Tim has been active in the venture capital and start-up ecosystem for over 20 years, initially as an entrepreneur and then as an investor with SoftBank, NEC and DFJ ePlanet Capital. He has been a party to more than 120 investments across a broad range of sectors, stages and geographies.

At BGF Tim is responsible for identifying and executing investments, with a particular focus on tech-orientated propositions.

Outside of work Tim spends as much of his time as possible on horseback and, in the interest of combining work with pleasure, keeps a horse specifically for long conference calls. Tim has a science background and began his career in BT’s research labs developing materials for optical switching and amplification. He has an MBA from London Business School.

Juliet joined the OrganOx board in January 2021 as a Non-Executive Director, appointed on behalf of the University of Oxford and the Technikos Parties, and Chair of the Audit Committee. Juliet has spent over 20 years actively involved in the life sciences sector working as an investment banker and strategic adviser to healthcare companies in Europe. She headed up the European healthcare team at Stifel (formerly Oriel) and prior to this was a founding partner of Code Securities, a healthcare investment banking boutique which was acquired by Nomura, later forming Nomura Code. Juliet sits on the boards of public companies Vectura plc and Novacyt S.A. and chairs the Audit Committee of both companies.